Sugi Predict

Sugi Predict / Compounds / SCHEMBL4014516

SCHEMBL4014516

SCHEMBL4014516

CC(C)S(=O)(=O)Cc1nc(Oc2ccc(F)cc2F)nc2[nH]nc(-c3ccccc3Cl)c12

nearest known ligand 0.42

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 10/20 0.42
▸ MAPK11 Q15759 1/20 0.42
▸ CREBBP Q92793 5/20 0.35
▸ SCN5A Q14524 1/20 0.34
▸ SCN9A Q15858 1/20 0.34
▸ TRPA1 O75762 1/20 0.34
▸ BRD4 O60885 1/20 0.33
▸ CTSA P10619 1/20 0.33
▸ PTGS1 P23219 1/20 0.33
▸ PTGS2 P35354 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4845106 0.91 MAPK14 (0.45) MAPK14MAPK11SCN5ASCN9ATRPA1
SCHEMBL4015508 0.90 MAPK14 (0.45) MAPK14MAPK11SCN5ASCN9ATRPA1
SCHEMBL4840911 0.89 MAPK14 (0.44) MAPK14MAPK11SCN5ASCN9ATRPA1
SCHEMBL4840764 0.89 MAPK14 (0.42) MAPK14MAPK11SCN5ASCN9ATRPA1
SCHEMBL4015305 0.88 MAPK14 (0.42) MAPK14MAPK11SCN5ASCN9ATRPA1
SCHEMBL4015527 0.88 MAPK14 (0.42) MAPK14MAPK11SCN5ASCN9ATRPA1
SCHEMBL4841631 0.84 MAPK14 (0.39) MAPK14MAPK11TRPA1CTSA
SCHEMBL4019409 0.83 MAPK14 (0.38) MAPK14MAPK11SCN5ASCN9ABRD4
SCHEMBL14019087 0.80 MAPK14 (0.42) MAPK14MAPK11SCN5ASCN9ATRPA1
SCHEMBL4840479 0.80 MAPK14 (0.42) MAPK14MAPK11SCN5ASCN9ATRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566708-B2 Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors ROCHE PALO ALTO LLC (US) 2009-07-28 — — US claimed
US-20070203160-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-08-30 — — US claimed
US-7566708-B2 Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors ROCHE PALO ALTO LLC (US) 2009-07-28 — — US disclosed
US-7566708-B2 Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors ROCHE PALO ALTO LLC (US) 2009-07-28 — — US disclosed
US-7566708-B2 Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors ROCHE PALO ALTO LLC (US) 2009-07-28 — — US disclosed
EP-1919470-A1 FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2008-05-14 — — EP disclosed
US-20070203160-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-08-30 — — US disclosed
US-20070203160-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-08-30 — — US disclosed
US-20070203160-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-08-30 — — US disclosed
WO-2007023105-A1 FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203160-A1 p38 MAP kinase inhibitors and methods for using the same MAPKAPK2, MAPK1, MAP3K2 MAPK14 33/4885MAPK11 46/4885CREBBP 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.